Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609161 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT06609161: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT06609161 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609161, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.
Primary Outcome
Blood samples will be collected to determine the AUC0-Inf of tedizolid.
Interventions
- DRUG Tedizolid Phosphate Oral Formulation 1 (Reference)
- DRUG Tedizolid Phosphate Oral Formulation 2 (Test)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2024-08-08 |
| Phase | Phase 1 |
What the finished NCT06609161 record still lists
NCT06609161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Tedizolid Phosphate Oral Formulation 1 (Reference) is the first listed.
NCT06609161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06609161 about?
NCT06609161 is a clinical study titled "A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)". The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.
What is the current status of trial NCT06609161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-07-16. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT06609161?
The interventions under investigation include: Tedizolid Phosphate Oral Formulation 1 (Reference) (DRUG), Tedizolid Phosphate Oral Formulation 2 (Test) (DRUG).
Who is sponsoring clinical trial NCT06609161?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06609161's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI